Generic Amvuttra Availability
Last updated on Apr 10, 2025.
Amvuttra is a brand name of vutrisiran, approved by the FDA in the following formulation(s):
AMVUTTRA (vutrisiran sodium - solution;subcutaneous)
-
Manufacturer: ALNYLAM PHARMS INC
Approval date: June 13, 2022
Strength(s): EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) [RLD]
Is there a generic version of Amvuttra available?
No. There is currently no therapeutically equivalent version of Amvuttra available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Amvuttra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Glycoconjugates of RNA interference agents
Patent 10,131,907
Issued: November 20, 2018
Inventor(s): Forst Andrea & Hadwiger Philipp & Vornlocher Hans-Peter
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
Patent expiration dates:
- August 24, 2028✓✓✓
- August 24, 2028
-
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Patent 10,208,307
Issued: February 19, 2019
Inventor(s): Zimmermann Tracy & Chan Amy & Jadhav Vasant & Maier Martin & Rajeev Kallanthottathil G.
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Patent expiration dates:
- July 28, 2036✓✓✓
- July 28, 2036
-
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Patent 10,570,391
Issued: February 25, 2020
Inventor(s): Rajeev Kallanthottathil G. & Zimmermann Tracy & Manoharan Muthiah & Maier Martin & Kuchimanchi Satyanarayana & Charisse Klaus
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
Patent expiration dates:
- November 16, 2032✓✓✓
- November 16, 2032
-
Modified double-stranded RNA agents
Patent 10,612,024
Issued: April 7, 2020
Inventor(s): Maier Martin & Foster Don & Milstein Stuart & Kuchimanchi Satya & Jadhav Vasant & Rajeev Kallanthottathil & Manoharan Muthiah & Parmar Rubina
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Patent expiration dates:
- August 14, 2035✓✓✓
- August 14, 2035
-
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Patent 10,683,501
Issued: June 16, 2020
Inventor(s): Zimmermann Tracy & Chan Amy & Jadhav Vasant R. & Maier Martin A. & Rajeev Kallanthottathil G.
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Patent expiration dates:
- July 28, 2036✓✓✓
- July 28, 2036
-
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent 10,806,791
Issued: October 20, 2020
Inventor(s): Manoharan Muthiah & Rajeev Kallanthottathil G. & Nair Jayaprakash & Maier Martin
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below:
Patent expiration dates:
- December 4, 2028✓
- December 4, 2028
-
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Patent 11,286,486
Issued: March 29, 2022
Inventor(s): Zimmermann Tracy & Chan Amy & Jadhav Vasant R. & Maier Martin A. & Rajeev Kallanthottathil G.
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Patent expiration dates:
- July 28, 2036✓✓✓
- July 28, 2036
-
Modified double-stranded RNA agents
Patent 11,401,517
Issued: August 2, 2022
Inventor(s): Maier; Martin et al.
Assignee(s): ALNYLAM PHARMACEUTICALS, INC. (Cambridge, MA)One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Patent expiration dates:
- August 14, 2035✓✓✓
- August 14, 2035
-
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Patent 12,049,628
Issued: July 30, 2024
Inventor(s): Zimmermann; Tracy et al.
Assignee(s): Alnylam Pharmaceuticals, Inc. (Cambridge, MA)The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Patent expiration dates:
- July 28, 2036✓✓✓
- July 28, 2036
-
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent 8,106,022
Issued: January 31, 2012
Inventor(s): Manoharan Muthiah & Rajeev Kallanthottathil G. & Narayanannair Jayaprakash K. & Maier Martin
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides iRNA agents comprising at least one subunit of the formula (I):
Patent expiration dates:
- December 12, 2029✓✓✓
- December 12, 2029
-
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent 8,828,956
Issued: September 9, 2014
Inventor(s): Manoharan Muthiah & Rajeev Kallanthottathil G. & Jayaprakash Narayanannair K. & Maier Martin
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides iRNA agents comprising at least one subunit of the formula (I):
Patent expiration dates:
- December 4, 2028✓✓✓
- December 4, 2028
-
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent 9,370,581
Issued: June 21, 2016
Inventor(s): Manoharan Muthiah & Rajeev Kallanthottathil G. & Nair Jayaprakash & Maier Martin
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.The present invention provides iRNA agents comprising at least one subunit of the formula (I):
Patent expiration dates:
- December 4, 2028✓✓✓
- December 4, 2028
-
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Patent 9,399,775
Issued: July 26, 2016
Inventor(s): Rajeev Kallanthottathil G. & Zimmermann Tracy & Manoharan Muthiah & Maier Martin & Kuchimanchi Satyanarayana & Charisse Klaus
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
Patent expiration dates:
- November 16, 2032✓✓✓
- November 16, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 13, 2027 - NEW CHEMICAL ENTITY
- June 13, 2029 - INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
More about Amvuttra (vutrisiran)
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.